Data have shown that influenza A virus in swine is significant and costly to the swine industry, especially when coinfection with other respiratory pathogens is present. The occurrence of IAV-S and porcine reproductive and respiratory syndrome simultaneously infecting pigs in late nursery can lead to average losses of as much as $18 per pig.1
In a new study to assess the impact of IAV-S vaccination in a known PRRS-unstable population, investigators measured average cumulative mortality in pigs vaccinated with Ingelvac Provenzacompared to those unvaccinated. Ingelvac Provenza is a live attenuated influenza vaccine that can be given to pigs during the neonatal period via intranasal administration.
Reduction in mortality with Ingelvac Provenza
Case study: The impact of vaccination with Ingelvac Provenza against IAV-S on mortality in a known PRRS-unstable population2
Objective: To assess the value of Ingelvac Provenza in pigs coinfected with IAV-S and PRRS in the nursery compared to pigs not vaccinated for IAV-S.
Investigators: C. Dykhuis Haden, B. Sexton, K. Cicconi-Hogan, C. Goodell
Method: In pigs coinfected with both IAV-S and PRRS, compare average cumulative nursery mortality in those vaccinated with Ingelvac Provenzato those left unvaccinated.
Key takeaway: After seven weeks, average cumulative nursery mortality was significantly lower in pigs vaccinated with Ingelvac Provenzacompared to those left unvaccinated for IAV-S.
The study included a growing pig flow sourced from five commercial sow farms in which all pigs received a commercial PRRS modified live vaccine vaccination at weaning. In September 2017, all five farms were confirmed IAV-S positive. In November, three of the commercial sow farms broke with abortion storms and classic respiratory PRRS. Despite implementing PRRS stabilization by means of mass vaccination, farms continued to leak wild type PRRS to downstream growing pigs.
Pigs were placed sequentially from mid-December 2017 through February 2018 into sites A through E. PRRS was detected at all sites throughout the study timeframe. The five wean-to-finish sites ranged from 4,451 to 17,853 pigs per site, where each site contained either 4 or 8 x 1,000 head rooms.
Mortality data were collected weekly. Of the five sites, sites A, B and D were left unvaccinated for IAV-S. Site C contained pigs vaccinated with Ingelvac Provenza at processing, while site E was vaccinated with Ingelvac Provenza at weaning. Mortality was summarized by week in the nursery for each treatment group.
By week seven, average cumulative nursery mortality for unvaccinated sites was 3.75% compared to 2.47% in Ingelvac Provenza vaccinated sites.
Supporting farrow-to-finish pig performance
This study has shown that vaccination with Ingelvac Provenza can be a valuable tool to improve the health and performance of pigs coinfected with both IAV-S and PRRS in the nursery phase.
For more information on how Ingelvac Provenza can help bring measurable value to influenza management, visit IngelvacProvenza.com.
References: 1. Stika R, Holtkamp MS, Goodell C, et al. Measuring the respiratory pathogen burden in growing pigs to estimate the impact of disease. In Allen D. Leman Swine Conference; September 15-18, 2018; St. Paul, MN. Poster. 2. Dykhuis Haden C, Sexton B, Cicconi-Hogan K, et al. The impact of vaccination with Ingelvac Provenza against IAV-S on mortality in a known PRRS-unstable population. In Proceedings from the American Association of Swine Practitioners Conference; March 9-12, 2019; Orlando, FL: 132.
Ingelvac Provenza is a registered trademark of Boehringer Ingelheim Vetmedica GmbH, used under license. 2019 Boehringer Ingelheim Animal Health USA Inc., Duluth, GA. All Rights Reserved. POR-1117-PRO1018 18825